Skip to main navigation
Rhythm Pharmaceuticals, Inc. Logo
  • Careers
  • Investors & Media
  • International
  • Search
  • Science
    • MC4R Pathway
    • Clinical Focus
    • Research & Development
  • Clinical Trials
  • Patients
    • Disease Focus
  • Product
  • About
    • Our People
    • Leadership
  • Science
    • MC4R Pathway
    • Clinical Focus
    • Research & Development
  • Clinical Trials
  • Patients
    • Disease Focus
  • Product
  • About
    • Our People
    • Leadership
  • Careers
  • Investors & Media
  • International
  • Search
  • Overview
  • Events & Presentations
  • Stock
  • Corporate Governance
  • Financials
    • SEC Filings
    • Quarterly Results
    • Annual Reports
  • News
  • IR Resources
    • Investor FAQs
    • Email Alerts
    • Contact Us

News
January 7, 2016
Rhythm Receives Orphan Drug Designation for Setmelanotide for the Treatment of Prader-Willi Syndrome
January 5, 2016
Rhythm and Camurus Announce License Agreement for Extended Release FluidCrystal Setmelanotide
December 11, 2014
Rhythm Appoints Fred T. Fiedorek, M.D., Chief Medical Officer
June 23, 2014
Rhythm Presents Clinical Data that RM-493 Increases Energy Expenditure in Obesity Study
September 24, 2013
Rhythm Initiates Clinical Trial of RM-493 for Obesity Caused by Genetic Variant
January 4, 2013
Rhythm Initiates Phase 2 Clinical Trial of RM-493 for Obesity
November 30, 2011
Rhythm Names Lex Van der Ploeg Chief Scientific Officer
November 9, 2011
Rhythm Names Keith M. Gottesdiener Chief Executive Officer
July 26, 2011
Rhythm Expands Scientific Advisory Board for Clinical Programs in Metabolic Diseases
March 12, 2010
Ipsen Grants Rhythm Exclusive Worldwide License for Two Programs in the Field of Metabolic Disorders
  • First page «
  • Previous page ‹
  • …
  • Page 26
  • Page 27
  • Current page 28
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • California Compliance

Rhythm Pharmaceuticals, Inc.
222 Berkeley Street, 12th Floor
Boston, MA 02116

This website is intended only for residents of the United States.

© 2024, Rhythm Pharmaceuticals, Inc. All Rights Reserved. Rhythm, IMCIVREE, GOLD Academy, LEAD for Rare Obesity, Uncovering Rare Obesity, and their logos are trademarks of Rhythm Pharmaceuticals, Inc.

US-RHY-2400016 05/2024